(Q73854958)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10840079%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

editorial

0 references

title

A PSA threshold of 4.0 ng/mL for early detection of prostate cancer: the only rational approach for men 50 years old and older (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10840079%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

H B Carter

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10840079%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

language of work or name

English

0 references

publication date

1 June 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10840079%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10840079%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

volume

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10840079%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10840079%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

page(s)

796-799

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10840079%20AND%20SRC:MED&resulttype=core&format=json

Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial

7 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900517-3

7 January 2021

Selection of optimal prostate specific antigen cutoffs for early detection of prostate cancer: receiver operating characteristic curves.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900517-3

7 January 2021

Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination. Enhancement of specificity with free PSA measurements

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900517-3

7 January 2021

Age-specific reference ranges for serum prostate-specific antigen in black men.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900517-3

7 January 2021

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900517-3

7 January 2021

Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900517-3

7 January 2021

Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900517-3

7 January 2021

Optimising the age, number of tests, and test interval for cervical screening in Canada

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900517-3

7 January 2021

Quantifying the potential benefit of CA 125 screening for ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900517-3

7 January 2021

Serial prostate specific antigen screening for prostate cancer: a computer model evaluates competing strategies

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2800%2900517-3

7 January 2021

10.1016/S0090-4295(00)00517-3

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10840079%20AND%20SRC:MED&resulttype=core&format=json

7 November 2019

1 reference